Cargando…

Variability in the Clinical Course of COVID-19 in a Retrospective Analysis of a Large Real-World Database

The COVID-19 pandemic proceeds in waves, with variable characteristics of the clinical picture resulting from the evolution of the SARS-CoV-2 virus. This study aimed to compare the epidemiological characteristics, symptomatology, and outcomes of the disease in patients hospitalized for COVID-19 duri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flisiak, Robert, Rzymski, Piotr, Zarębska-Michaluk, Dorota, Ciechanowski, Przemysław, Dobrowolska, Krystyna, Rogalska, Magdalena, Jaroszewicz, Jerzy, Szymanek-Pasternak, Anna, Rorat, Marta, Kozielewicz, Dorota, Kowalska, Justyna, Dutkiewicz, Ewa, Sikorska, Katarzyna, Moniuszko-Malinowska, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863894/ https://www.ncbi.nlm.nih.gov/pubmed/36680188 http://dx.doi.org/10.3390/v15010149

Ejemplares similares

Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings
por: Dobrowolska, Krystyna, et al.
Publicado: (2023)

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant
por: Flisiak, Robert, et al.
Publicado: (2023)

The association of airborne particulate matter and benzo[a]pyrene with the clinical course of COVID-19 in patients hospitalized in Poland()
por: Rzymski, Piotr, et al.
Publicado: (2022)

The Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases
por: Rorat, Marta, et al.
Publicado: (2022)

Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study
por: Moniuszko-Malinowska, Anna, et al.
Publicado: (2020)

Impact of Kidney Failure on the Severity of COVID-19
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Inflammatory and thrombotic parameters associated with the COVID-19 course in Poland (SARSTer study)
por: Czupryna, Piotr, et al.
Publicado: (2022)

Trends of infections and mortality due to hepatitis B virus (2005-2022) and the potential impact of the COVID-19 pandemic: a population-based study in Poland
por: Genowska, Agnieszka, et al.
Publicado: (2023)

Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy
por: Jaroszewicz, Jerzy, et al.
Publicado: (2022)

Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland
por: Rzymski, Piotr, et al.
Publicado: (2022)

Does Hospitalization Change the Perception of COVID-19 Vaccines among Unvaccinated Patients?
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
por: Flisiak, Robert, et al.
Publicado: (2021)

Demographic and Clinical Overview of Hospitalized COVID-19 Patients during the First 17 Months of the Pandemic in Poland
por: Flisiak, Robert, et al.
Publicado: (2021)

Updates in Management of SARS-CoV-2 Infection
por: Flisiak, Robert, et al.
Publicado: (2022)

Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals
por: Flisiak, Robert, et al.
Publicado: (2023)

Changing Epidemiological Patterns of Infection and Mortality Due to Hepatitis C Virus in Poland
por: Genowska, Agnieszka, et al.
Publicado: (2023)

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C
por: Brzdęk, Michał, et al.
Publicado: (2023)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study
por: Pawlowska, Malgorzata, et al.
Publicado: (2023)

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2023)

Perspectives of hepatitis C virus (HCV) elimination in Poland
por: Flisiak, Robert, et al.
Publicado: (2019)

Early oral antiviral use in patients hospitalised with COVID-19
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination
por: Flisiak, Robert, et al.
Publicado: (2021)

Ways to Eliminate Viral Hepatitis as a Global Health Threat
por: Flisiak, Robert, et al.
Publicado: (2022)

Searching for the optimal population for hepatitis C virus screening in Poland
por: Piekarska, Anna, et al.
Publicado: (2020)

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland
por: Pazgan-Simon, Monika, et al.
Publicado: (2023)

Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy
por: Flisiak, Robert, et al.
Publicado: (2021)

Reduced Vessel Density and Enlarged Foveal Avascular Zone in the Macula as a Result of Systemic Hypoxia Caused by SARS-CoV-2 Infection
por: Kal, Magdalena, et al.
Publicado: (2023)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
por: Tronina, Olga, et al.
Publicado: (2023)

Normalizing serum hepcidin but not α-1-antitrypsin level during effective treatment of chronic hepatitis C
por: Rogalska-Taranta, Magdalena, et al.
Publicado: (2017)

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine
por: Rzymski, Piotr, et al.
Publicado: (2021)

Viral hepatitis C treatment shortening – what is the limit?
por: Zarębska-Michaluk, Dorota
Publicado: (2019)

Genotype 3-hepatitis C virus’ last line of defense
por: Zarębska-Michaluk, Dorota
Publicado: (2021)

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era
por: Brzdęk, Michał, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lp2biqimljbo4bkoa7hp4en1rg